A Phase 1/2 Trial (CheckCell-2) in Patients with Metastatic Non-small Cell Lung Cancer (NSCLC) Administering Tumor-Infiltrating Lymphocytes (TILs) in Which the Gene Encoding CISH was Inactivated Using the CRISPR/Cas9 System
|Effective start/end date||10/10/22 → 10/31/27|
- INTIMA BIOSCIENCES, INC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.